AUSTIN, TX—(Marketwired – May 01, 2018) – Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its first quarter 2018 financial results on Wednesday, May 9, 2018. Savara management will also host a conference call for investors beginning at 5:30 p.m. ET on Wednesday, May 9, 2018 to discuss its first quarter 2018 financial results and to provide a business update.
Shareholders and other interested parties may access the conference call by dialing (855) 239–3120 from the U.S., (855) 669–9657 from Canada, and (412) 542–4127 from elsewhere outside the U.S. and requesting the Savara Inc. call. A live webcast of the conference call will be available online in the Investors section of Savara's website at http://www.savarapharma.com/investors/events/. Replays of the webcast will be available on Savara's website for 30 days and a telephone replay will be available through May 16th, 2018 by dialing (877) 344–7529 from the U.S., (855) 669–9658 from Canada, and (412) 317–0088 from elsewhere outside the U.S. and entering replay access code 10119917.
Savara Inc. is an orphan lung disease company. Savara's pipeline comprises: Molgradex, an inhaled granulocyte–macrophage colony–stimulating factor, or GM–CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara's strategy involves expanding its pipeline of potentially best–in–class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma)